Maialen Barrero
Overview
Explore the profile of Maialen Barrero including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
208
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gallardo-Gomez M, Costas-Rios L, Garcia-Prieto C, Alvarez-Rodriguez L, Bujanda L, Barrero M, et al.
Mol Oncol
. 2023 Dec;
18(11):2696-2713.
PMID: 38129291
The clinical relevance of the colorectal cancer serrated pathway is evident, but the screening of serrated lesions remains challenging. We aimed to characterize the serum methylome of the serrated pathway...
2.
Garcia-Etxebarria K, Etxart A, Barrero M, Nafria B, Segues Merino N, Romero-Garmendia I, et al.
Cancers (Basel)
. 2023 Oct;
15(19).
PMID: 37835382
Background: Some genetic polymorphisms (SNPs) have been proposed as predictors for different colorectal cancer (CRC) outcomes. This work aims to assess their performance in our cohort and find new SNPs...
3.
Garcia-Etxebarria K, Etxart A, Barrero M, Nafria B, Segues Merino N, Romero-Garmendia I, et al.
Cancers (Basel)
. 2022 Sep;
14(17).
PMID: 36077729
Although the genetic contribution to colorectal cancer (CRC) has been studied in various populations, studies on the applicability of available genetic information in the Basque population are scarce. In total,...
4.
Rescigno P, Gurel B, Pereira R, Crespo M, Rekowski J, Rediti M, et al.
Clin Cancer Res
. 2020 Sep;
27(2):566-574.
PMID: 32988971
Purpose: Cyclin-dependent kinase 12 (CDK12) aberrations have been reported as a biomarker of response to immunotherapy for metastatic castration-resistant prostate cancer (mCRPC). Herein, we characterize CDK12-mutated mCRPC, presenting clinical, genomic,...
5.
Mateo J, Seed G, Bertan C, Rescigno P, Dolling D, Figueiredo I, et al.
J Clin Invest
. 2019 Dec;
130(4):1743-1751.
PMID: 31874108
The genomics of primary prostate cancer differ from those of metastatic castration-resistant prostate cancer (mCRPC). We studied genomic aberrations in primary prostate cancer biopsies from patients who developed mCRPC, also...
6.
Zafeiriou Z, Bianchini D, Chandler R, Rescigno P, Yuan W, Carreira S, et al.
Eur Urol
. 2018 Oct;
75(1):184-192.
PMID: 30340782
Platinum-based regimens have not been proved to increase survival from advanced prostate cancer (PCa). Incontrovertible evidence that a proportion of prostate cancers have homologous recombination DNA (HRD) repair defects, and...